Galapagos’ alliance strategy combines novel targets and candidate drugs discovered by Galapagos with patient expertise from Galapagos’ pharma partners.  Galapagos runs these programs until candidate drug, Phase 1 or Phase 2, at which point the partner has the option to license the program. 


Indication Partner Established
Inflammation GlaxoSmithKline 2006
Inflammatory diseases  MorphoSys 2008
Osteoarthritis Servier 2010
Oncology Servier 2011
Rheumatoid arthritis/Crohn's disease  AbbVie  2012 
Cystic Fibrosis AbbVie 2013



© Copyright 2015 Galapagos NV | Disclaimer | General Purchase Terms